Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief
Authors:
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Climacteric
- Vol. 10 (2) , 120-131
Abstract
Objective To evaluate the efficacy of two ultra-low-dose 17β-estradiol plus norethisterone acetate (NETA) treatment regimens for relieving menopausal symptoms. Design A total of 577 postmenopausal women were enrolled, in three treatment groups in a double-blind, randomized, placebo-controlled study of 0.5 mg 17β-estradiol + 0.1 mg NETA or 0.5 mg 17β-estradiol + 0.25 mg NETA or placebo. Participants returned at weeks 4, 8, 12 and 24 for climacteric complaint evaluation based on a daily diary vasomotor symptom record. Patients were assessed by the Greene Climacteric Scale and urogenital symptoms were also evaluated. Results Treatment with ultra-low-dose 0.5 mg 17β-estradiol + 0.1 mg NETA (0.1 Group) or 0.5 mg 17β-estradiol + 0.25 mg NETA (0.25 Group) effectively reduced the severity and number of hot flushes within the initial weeks of therapy. Compared to placebo, a rapid, statistically significant decrease in the frequency and severity of hot flushes was achieved by week 3, followed by further improvement which continued throughout the study. There were no statistically significant differences between the active treatment arms. Conclusions The data show that both ultra-low-dose regimens are effective in reducing the severity and number of hot flushes compared to placebo, with good safety profiles.Keywords
This publication has 21 references indexed in Scilit:
- Practical recommendations for hormone replacement therapy in the peri- and postmenopauseClimacteric, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetateObstetrics & Gynecology, 1999
- Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patientsAmerican Journal of Obstetrics and Gynecology, 1999
- Progestogen intolerance and compliance with hormone replacement therapy in menopausal womenHuman Reproduction Update, 1997
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Efficacy and Local Tolerance of a Low-Dose, 7-Day Matrix Estradiol Transdermal System in the Treatment of Menopausal Vasomotor SymptomsObstetrics & Gynecology, 1996
- NAMS-Gallup Survey on Women??s Knowledge, Information Sources, and Attitudes to Menopause and Hormone Replacement TherapyMenopause, 1994
- Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosisBJOG: An International Journal of Obstetrics & Gynaecology, 1992
- A randomized double‐blind cross‐over trial into the effect of norethisterone on climacteric symptoms and biochemical profilesBJOG: An International Journal of Obstetrics & Gynaecology, 1982